Pulse nav.journalClub النقاشات النشطة الرائج استكشاف الباحثون

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

سياسة الخصوصية

الرئيسية استكشاف nav.journalClub الرائج

⌘+K

June 4, 2021Open Access

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy

Key Points

Key points are not available for this paper at this time.

Abstract

-Lu or close analogs may provide limited and acceptable toxicity while retaining efficacy in management of prostate cancer.

Like

Bookmark

Share

View Full Paper

Like

Bookmark

Share

View Full Paper

Cite This Study

Mease et al. (Fri,) studied this question.

synapsesocial.com/papers/6a01138564548b97a42d98fb https://doi.org/https://doi.org/10.2967/jnumed.121.262098

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer2021 · 30 citations
2Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen2015 · 110 citations
3Photoinduced energy transfer in associated, but noncovalently-linked photosynthetic model systems.1995 · 336 citations
4Preclinical evaluation of <sup>213</sup>Bi-/<sup>225</sup>Ac-labeled low-molecular-weight compounds for radiopharmaceutical therapy of prostate cancer2020 · 39 citations
5Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA2020 · 267 citations